-

Canopy Growth Appoints Miles Worne as Managing Director of European Markets

Appointment reinforces Canopy Growth’s focus on accelerating growth in Europe and delivering on its Global Medical strategy

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced the appointment of Miles Worne as Managing Director of European Markets, effective August 11, 2025.

Mr. Worne will be responsible for leading the Company’s commercial operations and go-to-market execution across the region. His appointment reflects a strategic investment in Europe, where Canopy Growth aims to deepen its presence in established medical markets and build the capabilities needed to support long-term expansion as new opportunities emerge.

“Europe represents one of the most compelling long-term growth opportunities for Canopy Growth,” said Luc Mongeau, Chief Executive Officer. “With a strong commercial background and deep experience in the cannabis sector navigating complex markets, Miles is well-positioned to help scale our presence in the region and support the delivery of our global medical strategy.”

Mr. Worne is an experienced commercial leader with over 20 years of global experience across the cannabis, healthcare, and consumer sectors. Most recently, he served as President of Curaleaf International, where he led the expansion of the company’s European medical cannabis operations. His background includes senior leadership roles in Europe, North America, and Asia at Glanbia Performance Nutrition and SlimFast International. Mr. Worne brings a strong track record of driving growth, building teams, and scaling businesses in regulated markets.

“I’m pleased to join Canopy Growth during a time of developing momentum in Europe,” said Miles Worne. “Canopy Growth is uniquely positioned with high-quality supply, trusted medical brands, and a growing presence in priority markets. I look forward to working with the team to build on this foundation and deliver meaningful growth in the region.”

The Company’s European operations are supported by European Union Good Manufacturing Practices (EU-GMP) certified supply from its Kincardine, Ontario facility, enhanced processing and distribution capabilities at its St. Leon-Rot facility in Germany, and a global supply chain infrastructure designed to meet the needs of patients and partners across the region.

About Canopy Growth
Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives.

Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.

Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC (“Canopy USA”). Canopy USA’s portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology.

At Canopy Growth, we’re shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we’re paving the way for a better understanding of all that cannabis can offer.

For more information visit www.canopygrowth.com.

Contacts

Alex Thomas
Director, Communications
alex.thomas@canopygrowth.com

Tyler Burns
Director, Investor Relations
tyler.burns@canopygrowth.com

Canopy Growth Corporation

TSX:WEED

Release Versions

Contacts

Alex Thomas
Director, Communications
alex.thomas@canopygrowth.com

Tyler Burns
Director, Investor Relations
tyler.burns@canopygrowth.com

More News From Canopy Growth Corporation

Canopy Growth Launches Claybourne Gassers Liquid Diamonds All-In-One Vapes in Canada, Expanding Footprint in High-Growth Vape Segment

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced the national launch of Claybourne Gassers, a new lineup of All-in-One (AIO) vapes featuring liquid diamonds. The launch marks Claybourne’s entry into Canada’s vape category, building on its leadership in high potency infused products. The Claybourne Gassers...

Canopy Growth Expands Spectrum Therapeutics Portfolio in Australia with New Softgels

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has expanded its Spectrum Therapeutics portfolio in Australia with the availability of new softgel capsules, further enhancing the Company’s medical cannabis offerings in the region. The formats include Spectrum Yellow Cannabis Oil Softgels (CBD 20mg), Spectrum Red Cannabis...

Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (Nasdaq: CGC) today announced its financial results for the second quarter ended September 30, 2025 ("Q2 FY2026"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. “We’re building a stronger, more competitive company defined by continued momentum in Canada adult-use cannabis, consistent growth in Canada medical cannabis, and...
Back to Newsroom